MX2022014637A - Composiciones y metodos para modular la actividad de deshidrogenasas de cadena corta. - Google Patents

Composiciones y metodos para modular la actividad de deshidrogenasas de cadena corta.

Info

Publication number
MX2022014637A
MX2022014637A MX2022014637A MX2022014637A MX2022014637A MX 2022014637 A MX2022014637 A MX 2022014637A MX 2022014637 A MX2022014637 A MX 2022014637A MX 2022014637 A MX2022014637 A MX 2022014637A MX 2022014637 A MX2022014637 A MX 2022014637A
Authority
MX
Mexico
Prior art keywords
activity
modulate
methods
compositions
short chain
Prior art date
Application number
MX2022014637A
Other languages
English (en)
Inventor
Joseph Ready
Monika Antczak
Stephen L Gwaltney
Sanford D Markowitz
Amar Desai
Stanton Gerson
Original Assignee
Rodeo Therapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rodeo Therapeutics Corp filed Critical Rodeo Therapeutics Corp
Publication of MX2022014637A publication Critical patent/MX2022014637A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Los compuestos y métodos para modular la actividad de 15-PGDH, modular los niveles de prostaglandina tisular, tratar enfermedades, trastornos de enfermedades o estados donde se desea modular la actividad de 15-PGDH y/o los niveles de prostaglandinas incluyen inhibidores de 15-PGDH descritos en el presente documento.
MX2022014637A 2020-05-20 2021-05-19 Composiciones y metodos para modular la actividad de deshidrogenasas de cadena corta. MX2022014637A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063027557P 2020-05-20 2020-05-20
PCT/US2021/033170 WO2021236779A1 (en) 2020-05-20 2021-05-19 Compositions and methods of modulating short-chain dehydrogenase activity

Publications (1)

Publication Number Publication Date
MX2022014637A true MX2022014637A (es) 2023-03-03

Family

ID=76444602

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022014637A MX2022014637A (es) 2020-05-20 2021-05-19 Composiciones y metodos para modular la actividad de deshidrogenasas de cadena corta.

Country Status (18)

Country Link
US (1) US20230192717A1 (es)
EP (1) EP4153299A1 (es)
JP (1) JP7819118B2 (es)
KR (1) KR20230053551A (es)
CN (1) CN116507626A (es)
AR (1) AR122137A1 (es)
AU (1) AU2021275122A1 (es)
BR (1) BR112022023576A2 (es)
CA (1) CA3183262A1 (es)
CL (2) CL2022003255A1 (es)
CO (1) CO2022018365A2 (es)
CR (1) CR20220654A (es)
IL (1) IL298043A (es)
MX (1) MX2022014637A (es)
PE (1) PE20230777A1 (es)
TW (1) TW202208376A (es)
UY (1) UY39225A (es)
WO (1) WO2021236779A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018102552A1 (en) 2016-11-30 2018-06-07 Case Western Reserve University Combinations of 15-pgdh inhibitors with corcosteroids and/or tnf inhibitors and uses thereof
US11718589B2 (en) 2017-02-06 2023-08-08 Case Western Reserve University Compositions and methods of modulating short-chain dehydrogenase
KR102921276B1 (ko) 2018-11-21 2026-02-03 케이스 웨스턴 리저브 유니버시티 단쇄 데히드로게나아제 활성을 조절하는 조성물 및 방법
CN114861214B (zh) * 2022-07-08 2022-10-14 智控天下(北京)商业管理有限公司 业务数据监控方法、设备、存储介质及装置
TW202434597A (zh) * 2022-11-14 2024-09-01 大陸商武漢人福創新藥物研發中心有限公司 抑制15-pgdh的化合物及其用途
TW202434211A (zh) * 2023-02-17 2024-09-01 大陸商武漢人福創新藥物研發中心有限公司 亞碸類化合物及其用途
AU2024310849A1 (en) * 2023-06-28 2026-01-29 Epirium Bio Inc. Intermittent dosing methods for treating a condition associated with increased 15-pgdh
WO2025039000A1 (en) * 2023-08-17 2025-02-20 New York Society for the Relief of the Ruptured and Crippled, maintaining the Hospital for Special Prevention and treatment of fibrosis through inhibition or upregulation of specific proteins

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US568159A (en) 1896-06-26 1896-09-22 Veneering-machine
US3382247A (en) 1965-11-01 1968-05-07 Upjohn Co 6-amino-1, 2-dihydro-1-hydroxy-2-imino-4-phenoxypyrimidines
US4910226A (en) 1987-04-29 1990-03-20 Smithkline Beckman Corporation Steroid 5-alpha-reductase inhibitors
LU87308A1 (fr) 1988-08-01 1990-03-13 Oreal Nouveaux derives de diamino-2,4 pyrimidine oxyde-3 et leur utilisation pour le traitement et la prevention de la chute des cheveux
US5015629A (en) 1989-06-26 1991-05-14 University Of Southern California Tissue repair
FR2651122B1 (fr) 1989-08-29 1994-10-28 Oreal Compositions destinees a etre utilisees pour freiner la chute des cheveux et pour induire et stimuler leur croissance, contenant des derives de l'amino-2 pyrimidine oxyde-3 et nouveaux composes derives de l'amino-2 pyrimidine oxyde-3.
US5480913A (en) 1989-09-27 1996-01-02 Arch Development Corporation Anti-androgen compounds
US5061620A (en) 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
US5635387A (en) 1990-04-23 1997-06-03 Cellpro, Inc. Methods and device for culturing human hematopoietic cells and their precursors
FR2662607B1 (fr) 1990-05-30 1992-08-28 Oreal Composition destinee a etre utilisee pour freiner la chute des cheveux et pour induire et stimuler leur croissance, contenant des derives d'alkyl-2 amino-4 (ou dialkyl-2-4) pyrimidine oxyde-3 .
US5411981A (en) 1991-01-09 1995-05-02 Roussel Uclaf Phenylimidazolidines having antiandrogenic activity
FR2677884B1 (fr) 1991-06-20 1993-07-09 Oreal Composition pour freiner la chute des cheveux a base de pyrimidines n-oxyde trisubstitues ou leurs derives sulfoconjugues, nouveaux composes pyrimidines n-oxyde ou leurs derives sulfoconjugues.
FR2678929A1 (fr) 1991-07-11 1993-01-15 Oreal Compositions pour freiner la chute des cheveux et pour induire et stimuler leur croissance a base de derives de 2,4-diamino pyrimidine 3-oxyde, nouveaux derives 2,4-diamino pyrimidine 3-oxyde.
FR2683531B1 (fr) 1991-11-13 1993-12-31 Rhone Poulenc Rorer Sa Nouveaux derives du lupane, leur preparation et les compositions pharmaceutiques qui les contiennent.
US5460964A (en) 1992-04-03 1995-10-24 Regents Of The University Of Minnesota Method for culturing hematopoietic cells
TW369521B (en) 1993-09-17 1999-09-11 Smithkline Beecham Corp Androstenone derivative
US5409813A (en) 1993-09-30 1995-04-25 Systemix, Inc. Method for mammalian cell separation from a mixture of cell populations
FR2711060B1 (fr) 1993-10-13 1995-11-17 Oreal Procédé pour modifier la pousse des poils et/ou des cheveux et compositions utilisables à cet effet.
SE9303444D0 (sv) 1993-10-20 1993-10-20 Kabi Pharmacia Ab New use of prostaglandins
FR2719481B1 (fr) 1994-05-05 1996-05-31 Oreal Composition à base de composés antifongiques et de composés antibactériens halogènes pour diminuer la chute des cheveux.
US5516779A (en) 1994-06-08 1996-05-14 Merck & Co., Inc. 17β-substituted-6-azasteroid derivatives useful as 5α-reductase inhibitors
US5677136A (en) 1994-11-14 1997-10-14 Systemix, Inc. Methods of obtaining compositions enriched for hematopoietic stem cells, compositions derived therefrom and methods of use thereof
US5807895A (en) 1994-11-29 1998-09-15 Schwarz Pharma, Inc. Use of prostaglandin E1, E2 or analogs to prevent renal failure induced by medical tests that utilize contrast media agents
US5529769A (en) 1994-12-20 1996-06-25 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Cosmetic compositions containing betulinic acid
FR2732597B1 (fr) 1995-04-05 1997-05-16 Oreal Utilisation dans une composition en tant qu'activateur et/ou stabilisateur de cyclooxygenase d'au moins un derive de pyrimidine substitue en 6
US5631282A (en) 1995-06-07 1997-05-20 Merck & Co., Inc. Triterpenes
JPH10215356A (ja) 1996-11-27 1998-08-11 Fuji Photo Film Co Ltd 再プリント用写真画像データの保管方法およびシステム
DE69823852T2 (de) 1997-02-04 2005-05-19 Johnstone, Murray A., Seattle Verfahren zur förderung des haarwuchses und entwicklung des haarsystems
AU755225B2 (en) 1997-12-12 2002-12-05 University Of Southern California Wound healing compositions
US20020037914A1 (en) 2000-03-31 2002-03-28 Delong Mitchell Anthony Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
US20020146439A1 (en) 2000-03-31 2002-10-10 Delong Mitchell Anthony Compositions and methods for treating hair loss using oximyl and hydroxylamino prostaglandins
WO2001072268A1 (en) 2000-03-31 2001-10-04 Toray Industries, Inc. Hair growth or hair formation controlling agents
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
FR2812190B1 (fr) 2000-07-28 2003-01-31 Oreal Utilisation d'agonistes non prostanoiques des recepteurs des prostaglandines ep-2 et/ou ep-4 comme agent cosmetique permettant d'attenuer, de diminuer ou d'arreter la chute des cheveux et des poils
FR2812191B1 (fr) 2000-07-28 2003-10-17 Oreal Utilisation d'agonistes du recepteur des prostaglandines e2 (ep-3) pour attenuer, diminuer ou stopper la pousse des cheveux et des poils dans des preparations cosmetiques
FR2825261B1 (fr) 2001-06-01 2003-09-12 Maco Pharma Sa Ligne de prelevement du sang placentaire comprenant une poche de rincage
US7147626B2 (en) 2004-09-23 2006-12-12 Celgene Corporation Cord blood and placenta collection kit
BRPI0721430A2 (pt) * 2007-03-09 2013-01-08 High Point Pharmaceuticals Llc amidas indol e benzimidazol como inibidoras de hidroxiesteràide deidrogenase
WO2016144958A1 (en) * 2015-03-08 2016-09-15 Case Western Reserve University Inhibitors of short-chain dehydrogenase activity for treating fibrosis
WO2013158649A1 (en) 2012-04-16 2013-10-24 Case Western Reserve University Compositions and methods of modulating 15-pgdh activity
EP2922543B1 (en) 2012-11-20 2017-05-24 Merck Sharp & Dohme Corp. Substituted pyridone derivatives as pde10 inhibitors
US9789116B2 (en) 2013-10-15 2017-10-17 Case Western Reserve University Compositions and methods of modulating short-chain dehydrogenase activity
JP2018511616A (ja) * 2015-04-14 2018-04-26 ケース ウエスタン リザーブ ユニバーシティ 短鎖デヒドロゲナーゼ活性を調節する組成物および方法
EP3484473A4 (en) 2016-07-18 2020-03-18 Case Western Reserve University INHIBITORS OF SHORT-CHAIN DEHYDROGENASE ACTIVITY TO PROMOTE NEUROGENESIS AND INHIBIT NERVOUS DEATH
WO2018102552A1 (en) 2016-11-30 2018-06-07 Case Western Reserve University Combinations of 15-pgdh inhibitors with corcosteroids and/or tnf inhibitors and uses thereof
US11718589B2 (en) * 2017-02-06 2023-08-08 Case Western Reserve University Compositions and methods of modulating short-chain dehydrogenase
US11426420B2 (en) 2017-04-07 2022-08-30 Case Western Reserve University Inhibitors of short-chain dehydrogenase activity for treating coronary disorders
AU2018272108B2 (en) 2017-05-26 2022-09-15 Board Of Regents, The University Of Texas System Compositions and methods of modulating short-chain dehydrogenase activity
KR102921276B1 (ko) * 2018-11-21 2026-02-03 케이스 웨스턴 리저브 유니버시티 단쇄 데히드로게나아제 활성을 조절하는 조성물 및 방법
JP7027301B2 (ja) 2018-12-25 2022-03-01 アルタカ株式会社 スクリーン印刷用版枠
JP2020134242A (ja) 2019-02-15 2020-08-31 オリンパス株式会社 計測方法、計測装置、およびプログラム

Also Published As

Publication number Publication date
CO2022018365A2 (es) 2023-03-07
JP2023527279A (ja) 2023-06-28
EP4153299A1 (en) 2023-03-29
IL298043A (en) 2023-01-01
CN116507626A (zh) 2023-07-28
WO2021236779A1 (en) 2021-11-25
BR112022023576A2 (pt) 2023-02-07
CA3183262A1 (en) 2021-11-25
AR122137A1 (es) 2022-08-17
CR20220654A (es) 2023-08-24
TW202208376A (zh) 2022-03-01
WO2021236779A9 (en) 2022-01-13
AU2021275122A1 (en) 2022-12-15
JP7819118B2 (ja) 2026-02-24
KR20230053551A (ko) 2023-04-21
CL2022003255A1 (es) 2023-07-14
US20230192717A1 (en) 2023-06-22
CL2025000080A1 (es) 2025-03-21
PE20230777A1 (es) 2023-05-09
UY39225A (es) 2021-11-30

Similar Documents

Publication Publication Date Title
MX2022014637A (es) Composiciones y metodos para modular la actividad de deshidrogenasas de cadena corta.
CR20210328A (es) Composiciones y métodos para modular la actividad de deshidrogenasas de cadena corta
NZ796735A (en) Compositions and methods of modulating short-chain dehydrogenase activity
HK1250651A1 (zh) 调控短链脱氢酶活性的组合物和方法
WO2020163823A3 (en) Therapeutic agents and methods of treatment
CL2020002146A1 (es) Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer.
MY209419A (en) Protein tyrosine phosphatase inhibitors and methods of use thereof
PH12020552228A1 (en) Protein tyrosine phosphatase inhibitors and methods of use thereof
WO2021146536A8 (en) Therapeutic agents and methods of treatment
GEAP202416612A (en) Tricyclic urea compounds as jak2 v617f inhibitors
CO2025008531A2 (es) Inhibidores de malt1
CR20220280A (es) Terapia de combinación que comprende un inhibidor de alk2 y un inhibidor de jak2
EA202092064A1 (ru) Способы изменения состава тела
MX2023009723A (es) Inhibidores de tyk2 y sus usos.
MX2022002443A (es) Compuestos inhibidores de perk.
MX2023000164A (es) Métodos y composiciones para tratar la hemofilia.
WO2020068950A8 (en) Hdac1,2 inhibitors
CL2023001139A1 (es) Compuestos moduladores del cftr, composiciones y usos de estos
SA522431729B1 (ar) مركبات وطرق لعلاج أمراض متعلقة بالأوكسالات.
MX2023010918A (es) Metodos y composiciones para el tratamiento de enfermedades oculares.
MX2023013942A (es) Usos de un modulador de somatostatina para el tratamiento de enfermedades.
MX2025002176A (es) Inhibidores de tyk2 y usos de los mismos
MX2024014321A (es) Composiciones y formulaciones para uso de un inhibidor de pk para la prevención, tratamiento y mejora de enfermedades, condiciones y trastornos de la piel
MX2024006065A (es) Amidas heterociclicas y metodos de utilizacion de las mismas.
CO2025009498A2 (es) Formulaciones de bezuclastinib